Literature DB >> 16399229

The cytotoxic anti-tumor effect of MTH-68/H, a live attenuated Newcastle disease virus is mediated by the induction of nitric oxide synthesis in rat peritoneal macrophages in vitro.

András Hrabák1, Ildikó Csuka, Tamás Bajor, László K Csatáry.   

Abstract

Rat peritoneal macrophages were induced to produce high amounts of nitric oxide (NO) when rats were challenged by MTH68/H, (a live attenuated oncolytic Newcastle disease virus strain). The increase in NO production was observed to be viral particle dose dependent. The higher NO production measured could be due to the enhanced expression of NO synthase II enzyme. In addition, viral administration caused a higher macrophage cell count in the peritoneal cavity of treated rats. Interleukin-1 and granulocyte-monocyte colony stimulating factors were also produced by the induced macrophages. COS 7, a transformed cell line was killed by both NO donors and activated macrophages; the latter effect was markedly decreased in the presence of the inhibitors of NO production. Cytotoxic effect of NO was evidenced by the decrease of cell viability and proliferation of COS 7 cells. Excessive NO production may also be cytotoxic for macrophages themselves as proved by the addition of exogenous NO donors. These results strongly suggested the participation of induced NO synthesis of macrophages in the anti-tumor effect of MTH-68/H vaccine treatment.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16399229     DOI: 10.1016/j.canlet.2005.02.008

Source DB:  PubMed          Journal:  Cancer Lett        ISSN: 0304-3835            Impact factor:   8.679


  9 in total

1.  Conditioned effects of heroin on the expression of inducible nitric oxide synthase in the rat are susceptible to extinction and latent inhibition.

Authors:  Jennifer L Szczytkowski; Donald T Lysle
Journal:  Psychopharmacology (Berl)       Date:  2007-01-09       Impact factor: 4.530

Review 2.  Oncolytic Newcastle disease virus for cancer therapy: old challenges and new directions.

Authors:  Dmitriy Zamarin; Peter Palese
Journal:  Future Microbiol       Date:  2012-03       Impact factor: 3.165

3.  Type I interferon-sensitive recombinant newcastle disease virus for oncolytic virotherapy.

Authors:  Subbiah Elankumaran; Vrushali Chavan; Dan Qiao; Raghunath Shobana; Gopakumar Moorkanat; Moanaro Biswas; Siba K Samal
Journal:  J Virol       Date:  2010-02-10       Impact factor: 5.103

4.  Heroin-induced conditioned immunomodulation requires expression of IL-1β in the dorsal hippocampus.

Authors:  Jennifer L Szczytkowski; Christina Lebonville; Lee Hutson; Rita A Fuchs; Donald T Lysle
Journal:  Brain Behav Immun       Date:  2013-01-26       Impact factor: 7.217

5.  Genetically engineered Newcastle disease virus for malignant melanoma therapy.

Authors:  D Zamarin; A Vigil; K Kelly; A García-Sastre; Y Fong
Journal:  Gene Ther       Date:  2009-02-26       Impact factor: 5.250

Review 6.  Oncolytic virus therapy for cancer.

Authors:  Joe Goldufsky; Shanthi Sivendran; Sara Harcharik; Michael Pan; Sebastian Bernardo; Richard H Stern; Philip Friedlander; Carl E Ruby; Yvonne Saenger; Howard L Kaufman
Journal:  Oncolytic Virother       Date:  2013-09-23

Review 7.  Safety and clinical usage of newcastle disease virus in cancer therapy.

Authors:  Han Yuen Lam; Swee Keong Yeap; Mehdi R Pirozyan; Abdul Rahman Omar; Khatijah Yusoff; Abd Aziz Suraini; Noorjahan Banu Alitheen
Journal:  J Biomed Biotechnol       Date:  2011-10-26

8.  Effect of recombinant Newcastle disease virus transfection on lung adenocarcinoma A549 cells in vivo.

Authors:  Yulan Yan; Lijuan Jia; Jin Zhang; Yang Liu; Xuefeng Bu
Journal:  Oncol Lett       Date:  2014-09-25       Impact factor: 2.967

9.  In Vitro and In Vivo Metabolomic Profiling after Infection with Virulent Newcastle Disease Virus.

Authors:  Panrao Liu; Yuncong Yin; Yabin Gong; Xusheng Qiu; Yingjie Sun; Lei Tan; Cuiping Song; Weiwei Liu; Ying Liao; Chunchun Meng; Chan Ding
Journal:  Viruses       Date:  2019-10-18       Impact factor: 5.048

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.